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participation in the study, and every 6 months in the second 
year. Participation started as soon as possible following a 
diagnosis of (m)RCC. Random effects models were used to 
study associations between HRQoL and patient and disease 
characteristics, symptoms and treatment.
Results Eighty-seven patients with mRCC completed 304 
questionnaires. The average EORTC QLQ-C30 global health 
status was 69 (SD, 19) before progression and 61 (SD, 22) 
after progression of disease. Similarly, the average EQ-5D 
utility was 0.75 (SD, 0.19) before progression and 0.66 (SD, 
0.30) after progression of disease. The presence of fatigue, 
pain, dyspnoea, and the application of radiotherapy were 
associated with significantly lower EQ-5D utilities.
Conclusions Key drivers for reduced HRQoL in mRCC 
are disease symptoms. Since symptoms increase with pro-
gression of disease, targeted therapies that increase PFS are 
expected to postpone reductions in HRQoL in mRCC.
Keywords Health-related quality of life · EQ-5D · 
EORTC QLQ-C30 · Cost-effectiveness analysis · 
Metastatic renal cell carcinoma · Targeted therapy
Introduction
Renal cell carcinoma (RCC) accounts for 90% of all kidney 
cancers [1]. While the prognosis of patients with localised 
disease treated with surgery is relatively good, the progno-
sis of patients with advanced or metastatic disease is poor. 
Median overall survival (OS) ranges from 7.8 months for 
patients with a poor risk to 43.2 months for patients with a 
favourable risk according to the Heng criteria [2]. Besides 
the impact of metastatic renal cell carcinoma (mRCC) on 
survival, mRCC can be associated with severe symptoms, 
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Purpose Based on improvements of progression-free sur-
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(mRCC) have been approved. It is assumed that one of the 
benefits is a delay in health-related quality of life (HRQoL) 
deterioration as a result of a delay in progression of dis-
ease. However, little data are available supporting this rela-
tionship. This study aims to provide insight into the most 
important determinants of HRQoL (including progression 
of disease) of patients with mRCC.
Methods A patient registry (PERCEPTION) was created 
to evaluate treatment of patients with (m)RCC in the Neth-
erlands. HRQoL was measured, using the EORTC QLQ-
C30 and EQ-5D-5L, every 3 months in the first year of 
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such as cachexia and/or anorexia, asthenia and/or fatigue, 
pain, anaemia, and venous thromboembolism [3].
Since 2006, several new targeted therapies have been 
approved for the treatment of mRCC such as sunitinib, 
sorafenib, pazopanib and everolimus. In phase III studies, 
these therapies improved progression-free survival (PFS) of 
patients with mRCC over the diverse comparators [4–11], 
but the effect on OS was less pronounced, likely (partly) due 
to treatment crossover. It is assumed that one of the ben-
efits of the new therapies is a delay in HRQoL deterioration 
as a result of a delay in progression of disease. Clinicians 
feel that a better PFS translates into a better HRQoL [12], 
but little data are available supporting this relationship. In 
the context of the high prices of targeted therapies which 
form a strain on health care budgets, it is important to estab-
lish whether indeed a delay in progression delays HRQoL 
deterioration.
This study is the first to provide insight into the most 
important determinants of HRQoL (including progression 
of disease) of patients with mRCC using data from a patient 
registry in the Netherlands [13]. Additionally, this study 
aims to assess if the association between progression and 
HRQoL, if one exists, is also captured by measures used in 
economic evaluations to assess benefit (i.e. EQ-5D).
Patients and methods
Study population
A patient registry (i.e. PERCEPTION) was created to evalu-
ate treatment of patients with (m)RCC in the Netherlands. 
Patients with RCC (all stages) of any histological subtype 
diagnosed from 2011 until June 30th 2013 in 25 of 32 hos-
pitals (both general and academic) in three regions in the 
Netherlands were invited to participate, and fill out HRQoL 
questionnaires. Eligible patients were identified through the 
hospitals’ registration systems. Additionally, the Netherlands 
Cancer Registry (NCR), which maintains a cancer registra-
tion database of all cancer patients in the Netherlands, was 
used to ensure that no patients were missed.
The research protocol was approved by the medical eth-
ics committee of Radboud university medical center in 
Nijmegen (CMO Region Arnhem-Nijmegen) in May 2010. 
Informed consent was obtained from all patients participat-
ing in the HRQoL study.
Data collection
Cancer-specific HRQoL was measured using the EORTC 
(European Organisation for Research and Treatment of 
Cancer) QLQ-C30 questionnaire (v3.0) [14]. This measure 
includes five functional scales (physical, role, emotional, 
social and cognitive), three symptom scales (fatigue, nausea 
& vomiting and pain), a global health status/QOL scale and 
six single items (dyspnoea, insomnia, appetite loss, consti-
pation, diarrhoea and financial difficulties). In addition to 
the EORTC QLQ-C30, the EQ-5D-5L was used to meas-
ure HRQoL. The EQ-5D-5L is a preference-based generic 
measure, and measures HRQoL on five dimensions, i.e. 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension includes five severity 
levels [15]. Patients were sent a HRQoL questionnaire every 
3 months in the first year of participation in the study, and 
every 6 months in the second year. Participation started as 
soon as possible following a diagnosis of (m)RCC.
In addition to data on HRQoL, data on demographics, 
clinical and laboratory factors (to determine the patient’s 
risk group [16]) were collected retrospectively from individ-
ual patient records using uniform case report forms. Further-
more, data on treatment schemes and treatment endpoints 
(e.g. survival) were derived from patient records. Data col-
lection stopped at the end of 2013.
Statistical analyses
For each scale of the EORTC QLQ-C30, the average of the 
items that contributed to that scale was calculated. They 
were then linearly transformed in line with the EORTC 
QLQ-C30 scoring manual [17]. EQ-5D utilities were derived 
by combining the answers to the EQ-5D-5L with the Dutch 
EQ-5D- 5L tariff [18]. Mean EQ-5D utilities and HRQoL 
based on the EORTC QLQ-C30 were calculated by taking 
the average of the observations for each patient. The propor-
tion of reported problems for each EQ-5D dimension were 
presented by taking the modus (i.e. the level reported most 
frequently) across observations for each patient. If two or 
more modes exist, the highest level was taken.
HRQoL was evaluated separately for the periods before 
and after progression of disease. In the period before pro-
gression of disease, a further distinction was made between 
wait-and-see and treatment with (first-line) targeted therapy. 
Treatment was assumed to last until progression of disease. 
Response including progression of disease was defined 
based on RECIST (as mentioned in the radiology report). As 
a substitute (if unavailable) data managers were instructed 
to register the response as indicated by the physician in the 
medical record. Patients who did not start therapy within the 
follow-up period were assumed to wait for therapy during 
the entire follow-up.
Since data on HRQoL were clustered, random effects 
models [19] were used to study associations between 
HRQoL (i.e. EORTC QLQ-C30 global health status and 
EQ-5D utility) and patient and disease characteristics, 
symptoms and treatment. Use of random effects models 
ensured that multiple measurements from the same patient 
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were analysed appropriately and made it possible to distin-
guish between intraindividual and interindividual variation. 
Backward selection was used to select the covariates for the 
models; any non-significant covariates were excluded from 
the models one at a time (significance level of 0.20 for enter-
ing and 0.10 for removing the explanatory variables). To 
control for heteroscedasticity, random effects models with 
robust standard errors were estimated.
Additionally, random effects logit models [19] were used 
to study associations between the individual EQ-5D dimen-
sions and patient and disease characteristics, symptoms and 
treatment. EQ-5D levels were dichotomised into ‘no prob-
lems/(i.e. level 1) and ‘problems’ (i.e. levels 2–5).
Missing data regarding patient and disease characteristics 
were handled using multiple imputations by chained equa-
tions. This method generated imputations based on a set of 
imputation models, one for each variable with missing val-
ues [20].
The significance level was set at α = 0.10. Data analyses 
were conducted using STATA statistical analysis software 
(StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP).
Results
Four hundred eleven (m)RCC patients participating in the 
study completed 1630 questionnaires. The median number 
of questionnaires per patient was four (range 1–7). The num-
ber of questionnaires collected at each time point is provided 
in the Supplementary material (Fig. S1), as are the number 
of questionnaires per patient (Fig. S2). The average EORTC 
QLQ-C30 global health status of patients diagnosed with 
localised disease (336 patients, 1326 questionnaires) was 76 
(SD, 15), and the average EQ-5D utility was 0.82 (SD, 0.17).
Eighty-seven patients had mRCC (i.e. metastatic dis-
ease at initial presentation or after an initial diagnosis with 
localised disease). Of these patients, eighty-two percent 
were male, and the median age at diagnosis was 63 years 
(Table 1). Twenty-six percent of the population did not 
receive any systemic therapy during follow-up. Of the 
patients receiving systemic therapy, the majority (80%) was 
treated with first-line sunitinib. Twenty-three patients also 
received a second-line therapy within the follow-up period; 
the majority of these patients was treated with everolimus 
(13/23). Thirty-one patients received radiotherapy during 
follow-up.
In total, 304 questionnaires were completed by patients 
with mRCC and the median number of questionnaires per 
patient was three (range 1–7).
Table 2 shows HRQoL during the different stages of the 
disease. The mean EORTC QLQ-C30 global health status 
was 67 (SD, 19). Patients primarily experienced problems 
with role functioning (i.e. doing daily activities and pursu-
ing leisure time activities). Problems with emotional (i.e. 
feeling tense, irritable, depressed or worrying) and cognitive 
functioning (i.e. concentrating and remembering) were expe-
rienced less often. Symptoms most commonly reported were 
fatigue, pain, insomnia and dyspnoea. A statistically signifi-
cant difference was found between the EORTC QLQ-C30 
global health status before and after progression of disease, 
i.e. 69 (SD, 19) and 61 (SD, 22) (p = 0.022). All function-
ing scales significantly decreased, except for emotional and 
cognitive functioning. Two symptom scales significantly 
increased; patients reported more problems regarding dysp-
noea (p = 0.031) and diarrhoea (p = 0.057) after progression 
than before progression of disease.
In the period before progression of disease, a similar 
HRQoL was found for a period without therapy (i.e. wait-
and-see) and a period with therapy; mean EORTC QLQ-
C30 global health statuses were 69 (SD, 22) and 70 (SD, 
17), respectively. However, in the period before progression 
of disease, patients experienced fewer problems with emo-
tional functioning during a period with therapy compared to 
a period without therapy (p = 0.067). Additionally, patients 
reported fewer problems regarding constipation (p = 0.072), 
but more problems regarding diarrhoea during a period with 
therapy compared to a period without therapy (p = 0.005).
Table 1  Baseline characteristics at diagnosis
LLN lower limit of normal, ULN upper limit of normal, RCC renal 
cell carcinoma, MSKCC Memorial Sloan Kettering Cancer Center
Variable Patients (n = 87)
Male sex, n (%) 71 (82)
Age, median (range) 63 (40–79)
Non-clear cell pathology, n (%) 17 (20)
WHO performance status, n (%)
 0–1 82 (94)
 2–4 5 (6)
More than one metastatic site, n (%) 48 (55)
Liver metastasis, n (%) 15 (17)
Lung metastasis, n (%) 48 (56)
Bone metastasis, n (%) 21 (24)
Brain metastasis, n (%) 3 (3)
Haemoglobin < LLN, n (%) 46 (52)
Neutrophil count > ULN, n (%) 18 (21)
Platelet count > ULN, n (%) 19 (22)
Corrected serum calcium > ULN, n (%) 26 (30)
Lactate dehydrogenase >1.5 times ULN, n (%) 11 (12)
Time since RCC diagnosis <1 year 78 (90)
MSKCC risk score, n (%)
 Favourable 6 (7)
 Intermediate 54 (62)
 Poor 27 (31)
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The average EQ-5D utility was 0.74 (SD, 0.19). As with 
the EORTC QLQ-C30 global health status, a significant 
difference was found in EQ-5D utility before progression 
of disease and after progression of disease; the average 
EQ-5D utility before progression of disease was 0.75 (SD, 
0.19), whereas the average EQ-5D utility after progression 
of disease was 0.66 (SD, 0.30) (p = 0.032). In the period 
before progression of disease, no significant difference was 
found between a period without therapy (i.e. wait-and-see) 
and a period with therapy; mean utilities were 0.76 (SD, 
0.21) and 0.76 (SD, 0.18), respectively. In the Supplemen-
tary material, Figs. S3 and S4 provide a summary of mean 
EORTC QLQ-C30 global health statuses and mean EQ-5D 
utilities by time.
Figures 1 and 2 show the proportions of patients report-
ing levels 1–5 by EQ-5D dimension, before progression 
of disease and after progression of disease. Both before 
and after progression of disease, most problems were 
reported on the mobility, usual activities and pain/discom-
fort dimensions.
Univariable analyses show several relationships 
between disease characteristics, symptoms and treatment, 
and HRQoL (Table  3). Patients with brain metastases 
and patients with progression of disease reported a lower 
HRQoL than the other patients. Patients with more than one 
metastatic site or bone metastases reported a lower EQ-5D 
utility, a relationship that was not seen in the EORTC QLQ-
C30 global health status. Additionally, symptoms (i.e. 
fatigue, nausea and vomiting, pain, dyspnoea, insomnia, 
appetite loss, constipation and diarrhoea) were associated 
with a lower HRQoL. Lastly, patients treated with radio-
therapy reported a worse HRQoL than patients not treated 
with radiotherapy.
Multivariable analysis showed that the EORTC QLQ-
C30 global health status decreased with the presence of 
fatigue, pain and appetite loss. Furthermore, the presence 
Table 2  Health-related quality of life based on the EQ-5D and QLQ-C30
Obs observations
*Observations of patients who died within 90 days after being diagnosed with mRCC were excluded from this subgroup (n = 2), since these 
measurements would not contribute to the estimation of the HRQoL of a patient awaiting therapy
**Mean EQ-5D utility of these patients before progression of disease (n = 21) was 0.76 (0.23)
***Mean EORTC QLQ-C30 global health status of these patients before progression of disease (n = 21) was 69 (20)
Total
n = 87 patients 
(304 obs.)
Before progression
n = 81 patients (246 obs.)
After progression
n = 27 patients (58 obs.)
Mean (SD) Total mean (SD) No systemic therapy 
n = 47 (125 obs.*)
Mean (SD)
First-line therapy 
n = 50 (119 obs.)
Mean (SD)
Total mean (SD)
EQ-5D
 Utility 0.74 (0.19) 0.75 (0.19) 0.76 (0.21) 0.76 (0.18) 0.66 (0.30)**
EORTC QLQ-C30
 Global health status 67 (19) 69 (19) 69 (22) 70 (17) 61 (22)***
Functioning scales
 Physical functioning 69 (23) 71 (23) 73 (22) 69 (23) 62 (29)
 Role functioning 59 (28) 61 (29) 61 (30) 62 (29) 52 (33)
 Emotional functioning 79 (16) 80 (18) 77 (19) 82 (19) 73 (19)
 Cognitive functioning 80 (20) 80 (22) 81 (21) 79 (25) 76 (22)
 Social functioning 76 (22) 78 (22) 77 (20) 78 (22) 67 (28)
Symptom scales
 Fatigue 41 (25) 39 (27) 36 (27) 41 (27) 48 (30)
 Nausea and vomiting 12 (17) 13 (20) 8 (13) 17 (24) 10 (12)
 Pain 29 (24) 27 (24) 24 (25) 29 (26) 34 (30)
Single items
 Dyspnoea 24 (24) 23 (24) 23 (25) 26 (28) 29 (34)
 Sleeping 28 (26) 26 (27) 24 (27) 27 (30) 35 (31)
 Appetite loss 19 (26) 18 (25) 15 (26) 21 (26) 22 (32)
 Constipation 10 (17) 9 (17) 12 (24) 5 (10) 12 (21)
 Diarrhoea 20 (26) 19 (27) 13 (27) 23 (28) 22 (26)
 Financial difficulties 10 (18) 9 (18) 9 (21) 11 (19) 8 (21)
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of brain metastases and progression of disease were associ-
ated with a worse EORTC QLQ-C30 global health status. 
A similar association was found between fatigue and pain, 
and the EQ-5D utility. Furthermore, EQ-5D utility scores 
decreased with the presence of dyspnoea and treatment with 
radiotherapy.
Although the univariable analyses showed several rela-
tionships between disease characteristics (e.g. the presence 
of bone or brain metastases and progression of disease) 
and HRQoL, these characteristics were no longer asso-
ciated with a deterioration of HRQoL in multivariable 
analyses after correction for symptoms (at a significance 
level of 0.05 and 0.01, except for the presence of brain 
metastases in the model with the EORTC QLQ-C30 global 
health status as the dependent variable). This seems to 
imply that symptoms might increase due to progression of 
disease (and/or due to the spread of the cancer to the bone 
or brain), which explains the reduced HRQoL.
Table  4 shows that fatigue was associated with all 
EQ-5D dimensions, except with the mobility dimension; 
fatigue was associated with a greater frequency of prob-
lems regarding self-care, usual activities, pain/discomfort 
and anxiety/depression. Patients having pain reported 
problems with all EQ-5D dimensions more often, with 
the exception of anxiety/depression.
Fig. 1  Proportion of patients 
reporting levels 1–5 by dimen-
sion, before progression of 
disease
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Fig. 2  Proportion of patients 
reporting levels 1–5 by dimen-
sion, after progression of 
disease
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Discussion
In this study differences were found between the health-
related quality of life (HRQoL) of patients with metastatic 
renal cell carcinoma (mRCC) before and after progression 
of disease, with a reduced HRQoL after progression of 
disease. Progression of disease was no longer associated 
with a deterioration of HRQoL in multivariable analyses 
after correction for symptoms (at a significance level of 0.05 
and 0.01). In line with Wilson and Cleary [21], a relationship 
between disease characteristics and symptoms was expected, 
which could explain why disease characteristics (such as 
Table 3  Associations between HRQoL and patient and disease characteristics, symptoms and treatment
Several comorbidities at diagnosis were considered for inclusion in the multivariable analyses, but all appeared to be not significantly associated 
with HRQoL
SE standard error, NS not significant
*Significant at α = 0.1
**Significant at α = 0.05
***Significant at α = 0.01
EQ-5D utility EORTC QLQ-C30 global health status
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Coefficient SE Coefficient SE Coefficient SE Coefficient SE
Patient characteristics
 Male sex 0.077 0.069 NS 2.748 5.198 NS
 Age (per year) −0.001 0.002 NS −0.257 0.223 NS
 WHO performance score
  0–1
  2–4 −0.08 0.072 NS −5.919 7.304 NS
Disease characteristics
 More than one metastatic site −0.068* 0.035 NS −5.048 3.342 4.048* 2.276
 Presence of liver metastases −0.027 0.05 NS −3.992 4.779 NS
 Presence of lung metastases −0.021 0.041 NS 0.465 4.074 NS
 Presence of bone metastases −0.085** 0.04 NS −3.39 3.915 NS
 Presence of brain metastases −0.285* 0.17 NS −21.143* 10.239 −13.586*** 2.438
 MSKCC risk score
  Favourable
  Intermediate 0.015 0.062 NS −0.431 8.924 NS
  Poor 0.054 0.063 NS 2.485 9.22 NS
 Progression of disease −0.082** 0.036 NS −6.897* 3 −3.859* 2.249
 Disease duration (in months) −0.002 0.001 NS −0.081 0.117 NS
Symptoms
 Fatigue −0.004*** 0.001 −0.003*** 0.001 −0.451*** 0.035 −0.316*** 0.042
 Nausea and vomiting −0.001* 0.001 0.001** 0.001 −0.360*** 0.05 NS
 Pain −0.004*** 0 −0.002*** 0 −0.324*** 0.036 −0.143*** 0.035
 Dyspnoea −0.003*** 0 −0.001*** 0 −0.222*** 0.04 NS
 Sleeping −0.002*** 0 NS −0.219*** 0.035 NS
 Appetite loss −0.002*** 0 NS −0.274*** 0.034 −0.111*** 0.035
 Constipation −0.002*** 0.001 NS −0.186*** 0.054 NS
 Diarrhoea −0.001* 0 NS −0.089** 0.04 NS
Treatment
 Systemic therapy versus no 
systemic therapy
0.026 0.027 NS −0.487 2.408 NS
 Radiotherapy −0.150*** 0.042 −0.115*** 0.036 −10.017*** 3.306 NS
Model intercept 0.943*** 0.016 85.380*** 1.903
R2 (overall) 0.559 0.534
Wald test (p value) <0.001 <0.001
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progression) were no longer statistically significant in the 
multivariable analyses. Similarly, bone metastases were no 
longer associated with a deterioration of HRQoL in multi-
variable analyses. Since bone metastases can cause pain, 
then it is not surprising that bone metastases are not signifi-
cantly associated with HRQoL once pain is included in the 
analysis. This seems to imply that symptoms increase due 
to progression of disease (and/or due to the spread of the 
cancer to the bone), which explains the reduced HRQoL.
Besides the relationship between symptoms and HRQoL, 
a significant association was found between radiotherapy 
and HRQoL (in the model with the EQ-5D utility as the 
dependent variable). It is possible that this observed asso-
ciation is not due to radiotherapy itself, but to the selection 
of which mRCC patients are to receive radiotherapy. That 
is, radiotherapy is mostly reserved for palliation of local 
and symptomatic disease or to prevent the progression of 
metastatic disease in critical sites (i.e. bones and brain) [22]. 
Either way, radiotherapy appears to be a significant determi-
nant of HRQoL, even after correction for patient and disease 
characteristics (including bone and brain metastases) and 
symptoms.
The average EQ-5D utility of patients with mRCC was 
0.74 compared to an average of 0.84 (SD, 0.18) in the Dutch 
population aged 60 to 69 [18]. Most patients (74%) in the 
study population were treated with a targeted therapy (the 
majority received sunitinib). The average EQ-5D utility of 
these patients was 0.76 before progression of disease. In a 
study by Cella et al., a similar EQ-5D utility was reported 
for patients treated with sunitinib (i.e. 0.75) [23]. In the eco-
nomic evaluation of bevacizumab and sunitinib by Thomp-
son-Coon and colleagues [24], a health state utility of 0.78 
(95% CI 0.76–0.80) was used for progression-free survival 
and 0.70 (95% CI 0.66–0.74) for progressive disease. These 
utilities were derived from the data presented in the sunitinib 
submission to NICE and are somewhat higher than the utili-
ties that we found in our study. The economic evaluation of 
sunitinib by Remák and colleagues [25] was based on the 
results of a phase II trial of sunitinib as second-line treat-
ment in mRCC [26]; utilities of 0.72 and 0.76 were used 
Table 4  Associations between the EQ-5D dimensions and patient and disease characteristics, symptoms and treatment
Odds ratios based on models created using multivariable logistic regression
OR odds ratio, SE standard error
*Significant at α = 0.1
**Significant at α = 0.05
***Significant at α = 0.01
Mobility Self-care Usual activities Pain/discomfort Anxiety/depres-
sion
OR SE OR SE OR SE OR SE OR SE
Patient characteristics
 Male sex 0.149** 0.112 NS 0.095** 0.110 NS NS
 Age (per year) 1.078** 0.032 NS NS NS NS
Disease characteristics
 Presence of liver metastases 4.427* 3.395 NS NS NS NS
 Presence of lung metastases NS NS NS NS 0.300* 0.191
 Presence of bone metastases 4.733** 2.961 NS 15.054*** 14.768 NS NS
 MSKCC risk score
  Favourable
  Intermediate NS NS NS 0.041*** 0.049 NS
  Poor NS NS NS 0.143 0.176 NS
 Disease duration NS 1.073** 0.033 NS NS NS
Symptoms
 Fatigue NS 1.044*** 0.012 1.128*** 0.028 1.034*** 0.012 1.021** 0.010
 Nausea and vomiting 0.967** 0.015 NS NS NS NS
 Pain 1.029*** 0.009 1.030*** 0.010 1.029* 0.015 1.143*** 0.023 NS
 Dyspnoea 1.025*** 0.009 NS 1.024* 0.014 NS NS
 Sleeping NS NS NS NS 1.016* 0.009
 Appetite loss 1.031*** 0.011 NS NS NS NS
Treatment
 Radiotherapy NS 6.062*** 3.971 NS NS NS
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for progression-free survival (i.e. during treatment or rest, 
respectively), whereas utilities of 0.63 and 0.55 were used 
for progressive disease (i.e. during second-line treatment or 
after termination of second-line treatment, respectively). The 
latter utilities are below the utilities found in our study, but 
this might be explained by differences in the study popu-
lation, e.g. patients with progression on first-line cytokine 
therapy were enrolled in the phase II trial.
This study has several limitations that deserve men-
tioning. First, only 9% of the population (including those 
patients with RCC but not having metastatic disease) com-
pleted the 2-year follow-up period and filled in seven ques-
tionnaires. This is mainly because data collection stopped 
before many patients could be followed up for 2 years after 
diagnosis. That is, data collection stopped at the end of 2013, 
which meant that patients diagnosed after January 1st 2012 
were not able to complete the full follow-up period. There 
are no reasons to expect important differences between the 
patients who did and did not complete the 2-year follow-up.
Second, a significant association between WHO per-
formance status and HRQoL, and the MSKCC risk score 
and HRQoL was not found, although such a relationship 
would have been expected. The MSKCC risk score divides 
patients into three risk groups, and gives an indication of 
the life expectancy of patients with mRCC [16]. Whereas 
HRQoL was measured several times during the follow-up 
period, data on patient characteristics (e.g. WHO perfor-
mance status) and disease characteristics (e.g. laboratory 
factors, which are part of the MSKCC risk score) were col-
lected once before the start of each new treatment. As a 
consequence, too few observations on patient and disease 
characteristics might have been available to detect a sig-
nificant association between WHO performance status and 
the MSKCC risk score, and HRQoL. Similarly, a significant 
association between comorbidities and HRQOL might have 
been expected, but data on comorbidities were only collected 
once (at diagnosis) which might explain why a significant 
association was not found. Nevertheless, the impact of 
comorbidities on HRQoL might be captured to some extent 
through age. Age appeared not to be significantly associated 
with HRQoL.
A third limitation is that our study sample was too small 
to find any difference in EQ-5D utilities between different 
types of targeted therapies, while these therapies differ 
in toxicity profiles [27]. Nevertheless, although adverse 
events have a high impact on HRQoL, an association 
between adverse events and HRQoL would not be found 
if the proportion of patients with grade 3 or 4 adverse 
events is relatively low. Hypertension and fatigue are the 
most commonly reported grade 3 or 4 adverse events in the 
randomised phase 3 trial of sunitinib [4], but these adverse 
events occurred in only 8 and 7% of the population. 
Therefore, a very large sample size is needed to find any 
difference in EQ-5D utilities between different types of 
targeted therapies. Additionally, it is unknown whether the 
improved HRQoL due to prolonged PFS outweighs reduc-
tions in HRQoL due to treatment-related adverse events. 
Importantly, this study did not find differences in HRQoL 
of patients treated with systemic therapy and patients not 
treated with systemic therapy, or between periods with or 
without systemic therapy. However, this study may have 
been underpowered to find such differences.
A fourth limitation is that no data were collected in the 
PERCEPTION-registry on assistance provided to patients 
who reported problems on one or more of the function-
ing scales of the EORTC QLQ-C30, while these patients 
could have received assistance to relieve their complaints. 
For example, patients could have received care at home to 
help with dressing and washing or emotional support by a 
psychologist or another healthcare professional. As a con-
sequence, the impact of mRCC on HRQoL as presented in 
Table 2 might be underestimated.
Lastly, the total number of patients with mRCC was 233 
in the 2011–2013 Cohort of the PERCEPTION-registry 
[13], while only 87 patients filled in one or more question-
naires about HRQoL. A comparison of the patient and 
disease characteristics and outcomes (in terms of over-
all survival) showed that the patients in the current study 
had a more favourable prognosis than the other patients 
in the PERCEPTION-registry. The impact on HRQoL as 
we estimated in this study is expected to be small, since 
we presented HRQoL associated with different stages of 
the disease.
To conclude, key drivers for reduced HRQoL in mRCC 
are symptoms of the disease. Since this study showed 
that symptoms increase with progression of disease, tar-
geted therapies that increase PFS can help to delay loss in 
HRQoL. This study also showed that the EQ-5D is able 
to detect changes in HRQoL of patients with mRCC, as 
it found associations between well-known symptoms of 
mRCC and EQ-5D utilities. Similar associations were 
found between these symptoms and the disease-specific 
EORTC QLQ-C30.
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